Serum Lipase
Other marker
Lipase
Serum Lipase
Pancreatic enzyme that hydrolyses triglycerides. More sensitive and specific for pancreatic pathology than amylase. The preferred diagnostic marker for acute pancreatitis.
PED Notes
GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) cause pharmacological lipase elevations of 28-31% without clinical pancreatitis in the vast majority of users. Up to 8.3% of GLP-1 users will exceed 3x the upper limit of normal. GH at bodybuilding doses (4-10 IU/day) stimulates pancreatic enzyme production; exogenous insulin increases lipase by approximately 47%. Oral 17-alpha-alkylated AAS can cause pancreatitis through cholestatic and direct toxic mechanisms. Hypertriglyceridemia above 11.3 mmol/L is an independent pancreatitis risk factor, relevant for athletes on lipid-worsening compounds.
When high
When elevated (>60 U/L):
Immediate actions:
- Determine the cause: GLP-1 therapy, GH/insulin use, oral AAS, alcohol, or hypertriglyceridemia
- If on GLP-1 agonists: mild to moderate elevation (1-3x ULN) without symptoms is expected pharmacological effect, not pancreatitis. Compare to your baseline.
- Check amylase alongside lipase for cross-reference
- Check triglycerides: levels above 11.3 mmol/L can independently cause pancreatitis
If mildly elevated (60-180 U/L, 1-3x ULN) without symptoms:
- On GLP-1 therapy: This is the expected range. The LEADER trial showed lipase increases of 28-31% are normal. Document the reading and recheck at next scheduled bloodwork. No dose adjustment needed.
- On GH/insulin: Consider reducing GH dose or cycling off for 2-4 weeks, then recheck
- On oral AAS: Discontinue hepatotoxic orals (Dianabol, Winstrol, Superdrol). Recheck in 2-4 weeks.
- Eliminate alcohol completely during any protocol that stresses the pancreas
- NAC 600mg 2x/day and TUDCA 250-500mg/day for hepatobiliary support
If significantly elevated (>180 U/L, >3x ULN):
- Even without symptoms, 3x ULN warrants closer monitoring. Recheck in 1-2 weeks.
- If on GLP-1: up to 8.3% of users exceed 3x ULN without pancreatitis. The positive predictive value for actual pancreatitis at this threshold is less than 1%.
- If accompanied by severe abdominal pain (especially radiating to the back), nausea, and vomiting: seek medical attention immediately. Stop all PEDs and GLP-1 therapy pending evaluation.
- Imaging (abdominal CT or ultrasound) is warranted if symptoms are present
Prevention:
- Get baseline lipase before starting GLP-1 agonists, GH, insulin, or oral AAS protocols
- Recheck at 4-6 weeks after starting or dose-escalating GLP-1 therapy
- Keep triglycerides below 2.3 mmol/L: hypertriglyceridemia is the most modifiable pancreatitis risk factor
- Limit oral AAS cycles to 4-6 weeks maximum
- Avoid alcohol during all hepatotoxic compound cycles
- Lose weight gradually on GLP-1 (target <1 kg/week) to reduce gallstone risk. GLP-1 agonists increase gallbladder disease risk by 37%, and gallstones cause roughly 30% of pancreatitis cases.
When low
When low (<10 U/L):
- Rarely clinically significant in isolation
- Extremely low levels may suggest chronic pancreatic insufficiency or cystic fibrosis
- If accompanied by steatorrhea (fatty stools), malabsorption, or unintended weight loss, further pancreatic function testing is warranted
History Chart
Reading History
Frequently Asked Questions
Reference Ranges
Standard Range
VitalMetrics Range